.png)
Nurami Medical
Electrospun-nanofiber dural-repair patch for neurosurgery (ArtiFascia)
Latest event found: 10 Sep 2026 · about 1 month ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Nurami Medical is transitioning from development to early commercialization while advancing ArtiFix through first-in-human clinical evaluation. Its strategy combines US sales of the FDA-cleared ArtiFascia product with EIC-supported development of a next-generation dural sealant.
Efficiency Ratio
The company shows strong capital-to-development efficiency for a small team, progressing two biomaterial products from R&D toward commercialization and clinical validation, although public evidence of scale remains limited.
Evidence Signals
Nurami completed patient enrollment in the ongoing ArtiFix first-in-human pilot study across clinical sites in Europe; follow-up and clinical evaluation remain ongoing.
Nurami appointed Erez Rozenfeld as chairman of the board.
Nurami announced that preliminary US sales of ArtiFascia, its FDA-cleared sutureable dural repair graft, had begun.
Nurami completed Phase 1 milestones under its EIC-backed Art iFix grant, including preclinical testing, EU technical-file submission, and initial trial-country approvals, securing Phase 2 funding.
- About
- Israeli regenerative-medicine / medical-device company (HQ Haifa, Israel), founded in 2014 by Dr. Amir Bahar (Weizmann/Technion) and Nora Nseir Manassa (Technion; co-CEO/CTO). Nurami builds bio-surgical implants from electrospun nanofiber scaffolds that mimic native tissue. Its first product, ArtiFascia®, is a multilayer biomimetic dural-repair graft for neurosurgery — a resorbable patch that promotes neodura regeneration while a barrier layer prevents cerebrospinal-fluid leaks and bacterial penetration; FDA 510(k)-cleared (2023) and in early US commercial sales. A second product, ArtiFix® (a sutureless dural adhesive patch for spine/neurosurgery), is in development (EIC-backed, pre-FiH). ~$44M raised. Note: this is a civilian neurosurgical soft-tissue-repair implant; its combat-casualty relevance is thin and downstream (dural repair after penetrating head/spine trauma) — the weakest defense fit in the C12-03 set.
- Tags
- #durarepair #neurosurgery #electrospun #nanofiber #softtissue #regenerative #implant #fda #csfleak